Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00176579|
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : August 12, 2011
RATIONALE: Measuring bone mineral density may help doctors predict whether prostate cancer will come back. It may also help the study of prostate cancer in the future.
PURPOSE: This clinical trial is studying whether bone mineral density affects cancer recurrence in patients with early stage prostate cancer.
|Condition or disease||Intervention/treatment|
|Osteoporosis Prostate Cancer||Procedure: dual x-ray absorptiometry|
- Determine bone mineral density (BMD) in patients with clinically significant early stage prostate cancer.
- Determine whether patients who have a higher level of BMD and have had a radical prostatectomy for cure are less likely to have an early relapse (i.e., less than 3 years) than those patients with a low level of BMD.
OUTLINE: This is a case-controlled study followed by a prospective, longitudinal, cohort study.
Patients undergo bone mineral density (BMD) measurements by dual-energy x-ray absorptiometry with a densitometer. Posteroanterior measurements of the total hip are also recorded.
Patients also undergo blood collection to examine markers that provide evidence of systemic disease.
Patients are followed every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
|Study Type :||Observational|
|Actual Enrollment :||27 participants|
|Observational Model:||Case Control|
|Official Title:||Assessing Bone Mineral Density as a Risk Factor for Early Clinically Significant Prostate Cancer|
|Study Start Date :||June 2003|
|Primary Completion Date :||July 2008|
|Study Completion Date :||July 2008|
Procedure: dual x-ray absorptiometry
- Bone mineral density [ Time Frame: Baseline ]DXA scan will be done after patient signs consent and eligibilty is confirmed
- Prostate Specific Antigen [ Time Frame: Baseline, every 6 months for 3 years ]PSA will be measured to look for biochemical recurrence of prostate cancer
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00176579
|United States, New Jersey|
|Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School|
|New Brunswick, New Jersey, United States, 08903|
|Principal Investigator:||Stephen W. Marcella, MD, MPH||Rutgers Cancer Institute of New Jersey|